Colombian PROCAPS to develop a cannabis based drug to treat epilepsy

PROCAPS, a Colombian pharmaceutical company, has announced the development of the first cannabis based drug, specially designed to treat epilepsy. This is an important step for cannabis and for Colombia, a country that could now be considered a cannabis pioneer in the region. PROCAPS also announced that the FDA has given them the green light to export and commercialize the medicine.

The Colombian pharmaceutical company PROCAPS developed a Cannabidiol-based drug (CBD) for the treatment of refractory epilepsy in patients with Dravet Syndrome and Lennox Gastaut Syndrome. This would be the first medication based on a cannabis derivative developed in the Latin American country.

PROCAPS is a Colombian based company, located in the city of Barranquilla, an important port district that connects the country with the Caribbean. The company specializes in the manufacturing and commercialization of pharmaceutical products. PROCAPS has a strategic location, in a city that serves as a distribution hub where a big number of export and import businesses take place every day.

Cannabidiol (CBD) is a derivative of the cannabis plant, which is found in varying proportions depending on the strain. This component is not psychoactive and its use is intended for therapeutic purposes thanks to its multiple benefits as an anticonvulsant, anti-inflammatory, anxiolytic, antioxidant, among others.

If you want to know more about how the Colombian pharmaceutical industry is taking advantage of cannabis, how this new medicine will improve the health of some patients and to find out the latest cannabis news, download the Hemp.im mobile application.

Cannabidiol as an effective way to combat epilepsy

The Cannabidiol (CBD) of this innovative product has an anticonvulsant effect, reduces the crises in patients of 2 or more years of age, and most importantly, does not produce a psychoactive effect in patients. It should be noted that the use of Cannabidiol (CBD) in standardized and controlled formulations for the treatment of refractory or drug-resistant epilepsy in children and young people has guaranteed an anticonvulsant effect of up to 50%.

Also, Cannabidiol (CBD) should not be confused with THC or Tetrahydrocannabinol, a component that produces psychoactive effects such as altered perception. Although both are components of the cannabis plant, their effects are completely different and Cannabidiol (CBD) has been proven not to cause any secondary effects.

“PROCAPS has more than 40 years of experience and since its inception has focused its efforts on developing innovative medicines and services that meet the highest international standards. The company is offering differentiated solutions that contribute to improving the health of the communities with which we interact. With the launch of this new drug we want to tell Colombia, Latin America, and the world that the cannabis industry can be leveraged to help the well-being and quality of life of people suffering from different diseases,” said Yan Guzman, director of the PROCAPS pharmacy division.

The PROCAPS plant in Barranquilla is certified to export the drug and has an FDA certificate from the United States government agency that regulates food, medicine, and cosmetics.

A worldwide disease that can be treated using innovative methods

According to the World Health Organization, approximately 65 million people worldwide suffer from epilepsy, making it the most common chronic neurological disorder. Of this number, it is estimated that 70% of people with epilepsy could live without seizures if properly diagnosed and treated. In addition, it has been estimated that 80% of patients live in low- and middle-income countries.

Epilepsy is a chronic brain disease that leads to the development of recurrent seizures. These seizures are caused by abnormal electrical discharges that can cause alterations in a person’s movement, behavior, consciousness, and sensations. According to the World Health Organization (WHO), in Colombia, there are 650,000 people, or 1.3% of the country’s population, who suffer from refractory epilepsy.

__

(Featured image by James Coleman on Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Hemp.im, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in El Heraldo, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Hemp.im assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Hemp.im is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.